Edition:
United Kingdom

Cellular Biomedicine Group Inc (CBMG.OQ)

CBMG.OQ on NASDAQ Stock Exchange Global Market

16.95USD
23 Feb 2018
Change (% chg)

$-0.10 (-0.59%)
Prev Close
$17.05
Open
$17.20
Day's High
$17.35
Day's Low
$16.80
Volume
2,168
Avg. Vol
12,812
52-wk High
$22.75
52-wk Low
$5.15

Latest Key Developments (Source: Significant Developments)

Cellular Biomedicine Announces Plan To Configure Part Of Shanghai Facility
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP INC - ANNOUNCED PLAN TO CONFIGURE PART OF ITS FACILITY IN SHANGHAI WITH GE HEALTHCARE'S FLEXFACTORY PLATFORM.CELLULAR BIOMEDICINE-AFTER EXECUTION OF NON-BINDING LOI, SEES FLEXFACTORY TO BE OPERATIONAL IN CBMG-GE JOINT LABORATORY OF CELL THERAPY BY END OF 2018.  Full Article

Cellular Biomedicine Group reports qtrly ‍loss per share $0.43
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Cellular Biomedicine Group Inc :Cellular Biomedicine Group reports third quarter financial results and recent operational highlights.Cellular Biomedicine Group Inc- ‍$16.3 million cash and cash equivalents as of September 30, 2017 as compared to $27.3 million as of June 30, 2017​.Cellular Biomedicine Group Inc - Qtrly ‍loss per share $0.43​.Cellular Biomedicine Group Inc - Qtrly net sales and revenue $106,787 versus $10,012‍​.  Full Article

Thermo Fisher Scientific and Cellular Biomedicine announce partnership to develop manufacturing processes
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Cellular Biomedicine Group Inc :Thermo Fisher Scientific and Cellular Biomedicine Group announce strategic partnership to develop manufacturing processes.Cellular Biomedicine Group Inc - ‍partnership focuses on research and development of an automated cell therapy manufacturing system​.  Full Article

Cellular Biomedicine Group announces resale of up to 5.1 mln shares of common stock for sale by selling stockholders
Monday, 20 Jun 2016 

Cellular Biomedicine Group Inc :Resale of up to 5.1 million shares of common stock for sale by the selling stockholders - SEC filing.  Full Article

Cellular Biomedicine reports Q1 results
Monday, 9 May 2016 

Cellular Biomedicine Group Inc : Cellular Biomedicine Group Inc says cash and cash equivalents as of march 31, 2016 were $15.7 million compared to $14.9 million as of december 31, 2015 . Cellular biomedicine group reports first quarter 2016 financial results and provides business highlights .Q1 revenue $488,500 versus $603,400.  Full Article

BRIEF-Cellular Biomedicine Group Announces $30.6 Mln Investment From Sailing Capital Overseas Investment

* CELLULAR BIOMEDICINE GROUP ANNOUNCES $30.6 MILLION INVESTMENT FROM SAILING CAPITAL OVERSEAS INVESTMENT LTD.